Resuscitative effect of a gamma-aminobutyric acid B receptor antagonist on gamma-hydroxybutyric acid mortality in mice
- PMID: 15940094
- DOI: 10.1016/j.annemergmed.2004.12.013
Resuscitative effect of a gamma-aminobutyric acid B receptor antagonist on gamma-hydroxybutyric acid mortality in mice
Abstract
Study objective: In the present study, a number of compounds were tested to evaluate their efficacy in exerting a protective effect on gamma-hydroxybutyric acid (GHB)-induced mortality in mice. The drugs investigated were the gamma-aminobutyric acid B (GABA B ) receptor antagonist SCH 50911, the GABA A receptor antagonist bicuculline, the benzodiazepine receptor antagonist flumazenil, the putative GHB receptor antagonist NCS-382, the opioid receptor antagonist naltrexone, and the amino acid and possible neuromodulator, taurine.
Methods: All mice were initially treated with a lethal dose of GHB (7 g/kg, administered intragastrically). Once mice had displayed clear signs of GHB intoxication, animals from each group were treated acutely with either SCH 50911 (vehicle; 75, 150, and 300 mg/kg, administered intraperitoneally), bicuculline (vehicle; 2, 4, 6, and 8 mg/kg, administered intraperitoneally), flumazenil (vehicle; 1, 3, and 10 mg/kg, administered intraperitoneally), NCS-382 (vehicle; 50 and 200 mg/kg, administered intraperitoneally), naltrexone (vehicle; 3 and 10 mg/kg, administered intraperitoneally), or taurine (vehicle; 250 and 750 mg/kg, administered intraperitoneally). The various doses of each single drug were administered to 10 mice, randomly allocated throughout the experimental groups. Mortality was recorded every hour for the first 9 hours and subsequently 12, 18, and 24 hours after GHB injection.
Results: In each experiment, all vehicle-treated mice died within 24 hours of GHB injection. Doses of 150 and 300 mg/kg SCH 50911 produced a marked protection on GHB-induced mortality, evidenced by the death of only 0 of 10 and 2 of 10 mice in the 150- and 300-mg/kg SCH 50911 groups, respectively. In contrast, at all doses tested, bicuculline, flumazenil, NCS-382, naltrexone, and taurine were not observed to exert any protective effect on GHB-induced mortality (9 to 10/10 mice died in each treatment group).
Conclusion: These results suggest an involvement of the GABA B receptor, at least in rodents, in the mediation of the lethal effects of GHB.
Similar articles
-
Resuscitative treatments on 1,4-butanediol mortality in mice.Ann Emerg Med. 2006 Feb;47(2):184-9. doi: 10.1016/j.annemergmed.2005.10.011. Epub 2005 Dec 27. Ann Emerg Med. 2006. PMID: 16431232
-
Protection by the GABAB receptor antagonist, SCH 50911, of gamma-hydroxybutyric acid-induced mortality in mice.Eur J Pharmacol. 2004 Oct 25;503(1-3):77-80. doi: 10.1016/j.ejphar.2004.09.027. Eur J Pharmacol. 2004. PMID: 15496299
-
Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.Drug Alcohol Depend. 2009 Aug 1;103(3):137-47. doi: 10.1016/j.drugalcdep.2009.03.004. Epub 2009 May 14. Drug Alcohol Depend. 2009. PMID: 19446408
-
A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor.CNS Drug Rev. 2004 Fall;10(3):243-60. doi: 10.1111/j.1527-3458.2004.tb00025.x. CNS Drug Rev. 2004. PMID: 15492774 Free PMC article. Review.
-
Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug.Toxicol Rev. 2004;23(1):3-20. doi: 10.2165/00139709-200423010-00002. Toxicol Rev. 2004. PMID: 15298489 Review.
Cited by
-
GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.Curr Neuropharmacol. 2015 Jan;13(1):47-70. doi: 10.2174/1570159X13666141210215423. Curr Neuropharmacol. 2015. PMID: 26074743 Free PMC article. Review.
-
An investigation of flumazenil to antagonize gamma-hydroxybutyrate intoxication in a murine model.J Med Toxicol. 2006 Jun;2(2):68-70. doi: 10.1007/BF03161174. J Med Toxicol. 2006. PMID: 18072117 Free PMC article.
-
Metabolic Alterations Associated with γ-Hydroxybutyric Acid and the Potential of Metabolites as Biomarkers of Its Exposure.Metabolites. 2021 Feb 10;11(2):101. doi: 10.3390/metabo11020101. Metabolites. 2021. PMID: 33578991 Free PMC article. Review.
-
Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.J Inherit Metab Dis. 2007 Jun;30(3):279-94. doi: 10.1007/s10545-007-0574-2. Epub 2007 Apr 24. J Inherit Metab Dis. 2007. PMID: 17457693
-
Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.J Pharmacol Exp Ther. 2013 Apr;345(1):102-10. doi: 10.1124/jpet.112.202796. Epub 2013 Feb 7. J Pharmacol Exp Ther. 2013. PMID: 23392755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous